Flotation

Orchard to orchestrate $173m IPO
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Sutro seals $86m IPO
Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.
Principia achieves $122m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
Asarina diagnoses listing
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
Allogene calls for $100m IPO
The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.
Sutro starts IPO proceedings
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Ascentage approaches Hong Kong IPO
Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.
Principia Biopharma primes $86m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.

Other News

Sensyne Health senses $76m IPO
Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.
Allakos accomplishes $128m IPO
The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.
Constellation consummates $60m IPO
The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.
MeiraGTx goes public for $75m
UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.
Akasol plugs into public markets
Forty Seven fetches $112m in IPO
The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.

Editor's Picks

Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login

Not yet subscribed?

See your subscription offers here